NEUP MEXC RealStocks
Own real NEUP shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1

Last updated: 2026-11-19 05:33:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Neuphoria Therapeutics Inc. (NEUP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.29, with a market capitalization of $13.42M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.26 to $5.53. This page covers its latest market performance, valuation, price trends and company information.
$13.42M | |
$2.27 | |
$2.42 | |
$2.27 | |
$2.27 | |
23.91K | |
29.18K | |
-- | |
$5.53 | |
$2.26 | |
-- | |
2026-06-30 |
Neuphoria Therapeutics Inc. (NEUP) last closed at $2.29 as of 2026-11-19 00:31:00, up 0.66% ($0.02) from the previous close of $2.27.
During the latest regular trading session, NEUP traded between $2.27 and $2.42, with a volume of 23.91K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Neuphoria Therapeutics Inc. (NEUP) moved from $2.76 to $2.29, representing a decline of 17.21% ($0.47).
The stock traded between $2.26 and $2.86 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 25.64 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.8%
NEUP is currently trading at $2.29, placing it 0.8% of the way from its 52-week low of $2.26 to its 52-week high of $5.53. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Neuphoria Therapeutics Inc. (NEUP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NEUP, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between NEUP shares and USD.
NEUP Shares to USD
1.00 NEUP shares = 2.285 USD
Calculations are estimates based on the latest available price and are for reference only.